Our academic excellence in genomics and translational medicine means innovative genomic testing can advance clinical practice.
Our fully UKAS accredited Clinical Genomics service brings the latest technology, such as the Illumina NovaSeq 6000 high throughput DNA sequencer and laboratory automation, so that we can deliver cost effective, high throughput workflows for personalised medicine. We have a number of research Next Generation Sequencing (NGS) gene panels for solid tumour and haematological malignancies and collaborate with research teams to design new panels with bespoke content, or can run whole exome sequencing. Working closely with experts in oncology at the Royal Marsden and across the North Thames GLH, we can bring novel testing through new clinical trials to patients sooner.
Our innovative genomic practice has led to successful collaborations in new clinical trials, especially in sequencing of circulating tumour DNA from liquid biopsies for colorectal cancer (TRACC), breast cancer (PEARL) and paediatric cancer (CRUK Stratified Medicine). We have experience in delivering large national projects, such as 100,000 Genomes Project and programmes supported by Cancer Research UK include the National Lung Matrix trial for Lung and working together with the Institute of Cancer Research, we are leading in delivering genomic profiling of paediatric patients with a solid tumour.
Please contact us with your specific research requirements and for a quote.
Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers.
Cancer Discov. 2020 https://pubmed.ncbi.nlm.nih.gov/32958578/
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Lancet Oncol. 2020 https://pubmed.ncbi.nlm.nih.gov/32919527/
A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.
Eur J. Cancer 2019 https://pubmed.ncbi.nlm.nih.gov/31543384/
Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance.
Clin Cancer Res. 2020 https://pubmed.ncbi.nlm.nih.gov/31591187/
Cancer Discov. 2020 https://pubmed.ncbi.nlm.nih.gov/32238360/
Genomic landscape of platinum resistant and sensitive testicular cancers.
Nat Commun. 2020 https://pubmed.ncbi.nlm.nih.gov/32366847/
MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer.
Clin Cancer Res. 2020 https://pubmed.ncbi.nlm.nih.gov/31852830/
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
Nat Commun. 2020 https://pubmed.ncbi.nlm.nih.gov/32471999/
Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue.
Cell Rep. 2020 https://pubmed.ncbi.nlm.nih.gov/32375028/
The KDR (VEGFR-2) Genetic Polymorphism Q472H and c-KIT Polymorphism M541L Are Associated With More Aggressive Behaviour in Astrocytic Gliomas
Cancer Genomics & Proteomics 2020 https://pubmed.ncbi.nlm.nih.gov/33099473/
Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy.
Br J Haematol. 2020 https://pubmed.ncbi.nlm.nih.gov/33022753/
Evaluation of Xpert® BCR-ABL Ultra for the confirmation of BCR-ABL1 international scale conversion factors for the molecular monitoring of chronic myeloid leukaemia.
Int J Lab Hematol. 2020 https://pubmed.ncbi.nlm.nih.gov/32990400/
Dr Mike Hubank – Clinical Director
“Our comprehensive genomic tests for cancer allow patients to receive the most optimal treatment possible. As we work together with research teams, our tests are always ready to identify patients who could benefit from even the most recently approved treatments.”